about
Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cellsIntranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protectionUnpolarized release of vaccinia virus and HIV antigen by colchicine treatment enhances intranasal HIV antigen expression and mucosal humoral responses.Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.Immunity to intracellular Salmonella depends on surface-associated antigens.Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit.AB toxins: a paradigm switch from deadly to desirableSignificant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes.Serum antibodies protect against intraperitoneal challenge with enterotoxigenic Escherichia coliMucosal immunization against respiratory bacterial pathogens.Alternative routes of mucosal immunization in large animals.Mice intranasally immunized with a recombinant 16-kilodalton antigen from roundworm Ascaris parasites are protected against larval migration of Ascaris suum.Nanotechnology Applications to HIV Vaccines and Microbicides.Prospects for a T-cell receptor vaccination against myasthenia gravis.Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function.Mucosal vaccine adjuvants update.A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protectionOuter membrane antigens of the uropathogen Proteus mirabilis recognized by the humoral response during experimental murine urinary tract infection.Impairment by mucosal adjuvants and cross-reactivity with variant peptides of the mucosal immunity induced by injection of the fusion peptide PADRE-ELDKWA.Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C.Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilisNasal and pulmonary vaccine delivery using particulate carriers.Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary routeOral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cellsImmunization without needles.The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation.Adjuvant synergy: the effects of nasal coadministration of adjuvants.Bacterial-associated cholera toxin and GM1 binding are required for transcytosis of classical biotype Vibrio cholerae through an in vitro M cell model system
P2860
Q24656942-B65F1BBA-AE6B-445D-931D-07B9A253431AQ28744570-40B8894E-A536-4C59-9622-0C94D422E730Q34026061-72E1329D-2E80-482A-9AAE-EF2DC61AEFD7Q34296144-A6778793-1A90-4EB1-AB23-2CADE2111FD8Q34456080-16F1B578-17A1-4D72-B26B-A28DCE7E0D53Q34629092-58D9203B-E871-4F4A-ACB6-4FC4B7D01BBAQ35155875-08C40091-799B-4796-83E9-C636D6BE5E38Q35287340-D595F27C-D938-4258-BC9A-D9F7FABCFFEEQ35327809-87BEC861-4708-46C8-B271-88611F24F648Q35623339-64CBC56A-1765-410C-BC1F-E2A19271B989Q35675891-72A599DF-B7AB-42F6-98E1-9C0CF917A90DQ35802015-F897FFA2-C7A6-4F96-AFE1-96F63EDFB53AQ35890514-D560609A-4C52-4D99-8319-D7288AD27141Q36238694-CB7134BE-C661-42F9-8526-DE5889F56C38Q36517179-D97B9D96-F913-47D7-8FFC-0EF36EE08641Q36551840-646F28B7-ADD1-4C0A-B603-0DDF19F441BBQ36758075-B683D49E-05AD-4C6A-8CA3-4539A96AE2AAQ36787928-6B5452E3-8359-4716-905C-F2122DCB7444Q36845213-84F33A97-9ED5-43A1-BE6A-0CAD76605E34Q37057799-1321A3E0-8D24-4FAF-9EEB-C0DAC7415E81Q37427432-6CA2F57E-3FEC-4EA1-9307-4557C7BB5A88Q37623929-8860FD48-3E57-4EAC-A645-E2C3793C3A8BQ38465267-E1377468-CFAF-43A9-B79B-3C8F9F977165Q41950285-6D005A13-E8E3-418F-AE7B-1FBB1218A6E9Q42766901-0B9E1B03-5E8C-482C-9DFD-E87DDD18A326Q46308392-C8356456-8E29-430B-92D0-0FA1094EAA97Q46942390-0CA46A8C-DE87-4FB0-8193-D546BF3E7407Q47712275-50749DCE-BAD6-4EE5-BD14-7C53984016D8Q51996299-1437900A-D68F-4676-9D55-901D6BAE526AQ57374189-0582FC17-C7CE-455C-BB7F-142EC003B320
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Recent advances in mucosal vaccines and adjuvants.
@ast
Recent advances in mucosal vaccines and adjuvants.
@en
Recent advances in mucosal vaccines and adjuvants.
@nl
type
label
Recent advances in mucosal vaccines and adjuvants.
@ast
Recent advances in mucosal vaccines and adjuvants.
@en
Recent advances in mucosal vaccines and adjuvants.
@nl
prefLabel
Recent advances in mucosal vaccines and adjuvants.
@ast
Recent advances in mucosal vaccines and adjuvants.
@en
Recent advances in mucosal vaccines and adjuvants.
@nl
P1476
Recent advances in mucosal vaccines and adjuvants.
@en
P2093
Kristina Eriksson
P304
P356
10.1016/S0952-7915(02)00384-9
P50
P577
2002-10-01T00:00:00Z